NICARAVEN

Details

Stereochemistry	RACEMIC
Molecular Formula	C15H16N4O2
Molecular Weight	284.3131
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(CNC(=O)C1=CC=CN=C1)NC(=O)C2=CC=CN=C2

InChI

InChIKey=KTXBOOWDLPUROC-UHFFFAOYSA-N

InChI=1S/C15H16N4O2/c1-11(19-15(21)13-5-3-7-17-10-13)8-18-14(20)12-4-2-6-16-9-12/h2-7,9-11H,8H2,1H3,(H,18,20)(H,19,21)

HIDE SMILES / InChI

Description
Sources: http://www.selleckchem.com/datasheet/nicaraven-DataSheet.html | http://adisinsight.springer.com/drugs/800003066 | https://www.ncbi.nlm.nih.gov/pubmed/12625035

Nicaraven is a hydroxyl radical scavenger with antivasospastic and neuroprotective effects. Chugai (the Japanese subsidiary of Roche) is developing nicaraven (Antevas), a water-soluble antioxidant, for the potential treatment of disorders caused by acute cerebrovascular diseases. A registration application was filed in April 1995, and in April 2002, nicaraven was still awaiting registration in Japan. By August 2002, Chugai had filed an NDA in Japan for the additional indication of subarachnoidal bleeding.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
PARP 1, 2 and 3 9 Target ID: CHEMBL3390820 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17094462	Inhibitor 8297		1.5 mM [IC50]
Oxidative Stress 160 Target ID: WP408 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12625035	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Subarachnoid hemorrhage 10 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12625035 https://www.ncbi.nlm.nih.gov/pubmed/11060715	Primary		Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed

Patents

Sample Use Guides

In Vivo Use Guide

4 g nicaraven infused intravenously for 6-8 hours once a day

Route of Administration: Intravenous

In Vitro Use Guide

The antiplatelet activities in vitro of nicaraven were examined. The concentrations of nicaraven tested were 3.50 x 10(-5) mol/L, 1.75 x 10(-4) mol/L, 3.50 x 10(-4) mol/L, and 1.75 x 10(-3) mol/L, respectively. The maximum aggregation rate induced by adenosine diphosphate (ADP) was significantly inhibited by nicaraven at concentration ranges of 3.50 x 10(-4) mol/L or higher in the healthy volunteer platelets. The maximum aggregation rate induced by collagen was significantly inhibited by 1.75 x 10(-3) mol/L of nicaraven. Using platelets from patients with cerebral thrombosis, the maximum aggregation rate induced by ADP was significantly inhibited by 1.75 x 10(-3) mol/L of nicaraven. Furthermore, the maximum aggregation rate induced by collagen were significantly reduced by 1.75 x 10(-3) mol/L of nicaraven.

Name

Type

Language

NICARAVEN

Official Name

English

NICARAVEN [MI]

Common Name

English

nicaraven [INN]

Common Name

English

AVS

Common Name

English

1,2-BIS(NICOTINAMIDO)PROPANE

Systematic Name

English

NICARAVEN [MART.]

Common Name

English

NICARAVEN [JAN]

Common Name

English

ANTEVAS

Common Name

English

(±)-N,N'-PROPYLENEBIS(NICOTINAMIDE)

Systematic Name

English

3-PYRIDINECARBOXAMIDE, N,N'-(1-METHYL-1,2-ETHANEDIYL)BIS-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C333